Hims & Hers Health (NYSE:HIMS) Insider Sells $367,870.91 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Patrick Harrison Carroll sold 10,021 shares of the stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total transaction of $367,870.91. Following the sale, the insider owned 169,940 shares of the company’s stock, valued at approximately $6,238,497.40. This represents a 5.57% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Hims & Hers Health Stock Performance

NYSE HIMS traded down $0.23 during trading on Thursday, reaching $34.74. The company’s stock had a trading volume of 11,410,870 shares, compared to its average volume of 30,867,883. The business’s fifty day moving average price is $42.69 and its 200-day moving average price is $48.78. Hims & Hers Health, Inc. has a twelve month low of $23.97 and a twelve month high of $72.98. The company has a debt-to-equity ratio of 1.67, a quick ratio of 1.64 and a current ratio of 1.88. The firm has a market cap of $7.91 billion, a price-to-earnings ratio of 64.33, a P/E/G ratio of 7.29 and a beta of 2.41.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, November 3rd. The company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.03). Hims & Hers Health had a return on equity of 24.67% and a net margin of 6.05%.The business had revenue of $598.98 million for the quarter, compared to analyst estimates of $578.99 million. During the same quarter last year, the company posted $0.32 EPS. Hims & Hers Health’s quarterly revenue was up 49.2% on a year-over-year basis. As a group, analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Hims & Hers Health announced that its board has authorized a share repurchase program on Monday, November 17th that authorizes the company to buyback $250.00 million in shares. This buyback authorization authorizes the company to purchase up to 3% of its shares through open market purchases. Shares buyback programs are generally a sign that the company’s management believes its shares are undervalued.

Analyst Ratings Changes

Several research analysts have weighed in on HIMS shares. Wall Street Zen downgraded Hims & Hers Health from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. BTIG Research reaffirmed a “buy” rating and set a $85.00 price target on shares of Hims & Hers Health in a report on Tuesday, November 4th. UBS Group set a $32.00 price objective on shares of Hims & Hers Health in a research note on Tuesday, November 4th. KeyCorp started coverage on shares of Hims & Hers Health in a research report on Tuesday, October 21st. They set a “sector weight” rating for the company. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Hims & Hers Health in a research note on Monday. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, ten have issued a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $45.50.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Vanguard Group Inc. lifted its holdings in Hims & Hers Health by 4.5% in the third quarter. Vanguard Group Inc. now owns 19,518,015 shares of the company’s stock valued at $1,107,062,000 after acquiring an additional 844,991 shares during the period. Capital World Investors increased its holdings in shares of Hims & Hers Health by 1.2% in the 3rd quarter. Capital World Investors now owns 18,783,194 shares of the company’s stock valued at $1,065,399,000 after purchasing an additional 223,892 shares in the last quarter. Farallon Capital Management LLC increased its holdings in shares of Hims & Hers Health by 30.8% in the 3rd quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock valued at $609,561,000 after purchasing an additional 2,533,271 shares in the last quarter. State Street Corp lifted its stake in shares of Hims & Hers Health by 1.9% in the third quarter. State Street Corp now owns 7,173,214 shares of the company’s stock valued at $406,865,000 after purchasing an additional 132,384 shares during the period. Finally, Geode Capital Management LLC lifted its stake in shares of Hims & Hers Health by 1.5% in the second quarter. Geode Capital Management LLC now owns 4,746,081 shares of the company’s stock valued at $236,622,000 after purchasing an additional 71,593 shares during the period. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.